ASCO/CAP analyzed factors affecting receptor conversion, such as specimen handling, tissue fixation, and analytical assay methods; used 1% as the optimal cutoff for ER/PR positivity; and recommended that endocrine therapy for this subset of breast cancer patients could help mitigate biomarker changes and their possible adverse effects (31–33). The gene discussed is ESR1; the disease is breast cancer.